13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-06-15 Event 2026-06-10 SEC 0002134649-26-000001 →

Schoeni Gilbert Edgar Veraxa Biotech Holding AG VRXAW

Stake: 15.90% Shares: 22,539,749 CUSIP: H9130A111 Class: Ordinary Shares, par value CHF 100/11325 per share

Item 4 — Purpose of Transaction

The Reporting Person acquired the PubCo Ordinary Shares reported herein in connection with the closing of the Business Combination as described in Item 3 above. The Reporting Person acquired the PubCo Ordinary Shares for investment purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, the Issuer's financial condition, results of operations, share price and other relevant factors, the Reporting Person may from time to time acquire additional PubCo Ordinary Shares, dispose of all or a portion of the PubCo Ordinary Shares beneficially owned by the Reporting Person, or take any other available courses of action (which may include, without limitation, any plans or proposals described in clauses (a)-(j) of Item 4 of Schedule 13D), in any case in one or more transactions. The Reporting Person does not have any present plans or proposals which relate to or would result in any of the actions specified in Item 4(a)-(j) of Schedule 13D, except as described below: As described in Item 6 below, the Reporting Person is party to that certain Voting, Support and Lock-Up Agreement among SPAC, the Company, and certain shareholders of the Company (the "Company Shareholder Support Agreement"), pursuant to which the Reporting Person agreed, among other things, not to transfer certain PubCo Ordinary Shares for a specified period following the Acquisition Closing, subject to certain exceptions. In addition, the Company Shareholders have the right to receive an aggregate of up to 5,000,000 additional PubCo Ordinary Shares (the "Earnout Shares") during each of the three fiscal years after the Closing Date, in the event that: (i) the volume-weighted average price ("VWAP") of the PubCo Ordinary Shares equals or exceeds $11.00 for 20 trading days during any 30 consecutive trading day period prior to December 31, 2026; (ii) the VWAP equals or exceeds $12.50 for 20 trading days during any 30 consecutive trading day period prior to December 31, 2027; and (iii) the VWAP equals or exceeds $14.00 for 20 trading days during any 30 consecutive trading day period prior to December 31, 2028.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 1.00
597 shares short · -58.6% vs prior

Post-Filing Returns · since 2026-06-10 on VRXAW

+1 day
0.0%
+5 days
0.0%
+30 days
0.0%
+60 days
+90 days
+180 days

Anchor price 0.12 on closest trading day on/after 2026-06-10. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on Veraxa Biotech Holding AG

FiledFormFilerStakeShares
2026-06-16 SCHEDULE 13D Deck David Lukas 18.00% 25,502,836 view →
2026-06-16 SCHEDULE 13D European Molecular Biology Laboratory 16.20% 22,891,235 view →
2026-06-15 SCHEDULE 13D Xlife Sciences AG 16.30% 23,029,967 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →